Economic Analysis of Nutrition Interventions: Methods, Research and Policy, 68845 [E9-30683]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 248 / Tuesday, December 29, 2009 / Notices
Company Superfund Site, Texas City,
Galveston County, Texas, and EPA
Docket Number 06–17–07, and should
be addressed to Patrice Miller at the
address listed above.
FOR FURTHER INFORMATION CONTACT:
Anne Foster, 1445 Ross Avenue; Dallas,
Texas 75202–2733 or call (214) 665–
2169 or I-Jung Chiang, 1445 Ross
Avenue, Dallas, Texas 75202–2733 or
call (214) 665–2160.
Dated: December 14, 2009.
Al Armedariz,
Regional Administrator, Region 6.
[FR Doc. E9–30819 Filed 12–28–09; 8:45 am]
BILLING CODE 6560–50–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Economic Analysis of Nutrition
Interventions: Methods, Research and
Policy
pwalker on DSK8KYBLC1PROD with NOTICES
Notice
Notice is hereby given of the National
Institutes of Health (NIH) Office of
Dietary Supplements (ODS) Economic
Analysis of Nutrition Interventions
Workshop to be held February 23–24,
2010 at the Bethesda North Marriott
Hotel & Conference Center in Bethesda,
Maryland, 20852.
Summary
In 2008, healthcare expenditures in
the U.S. were estimated to be 17% of
GDP, and these projected expenditures
were largely associated with chronic
disease. Medicare beneficiaries spent a
median of 16% of their incomes on
healthcare, and if current trends persist,
a family earning $60,000 ‘‘gross wage
base’’ will be spending more than 41%
of wages on healthcare in 10 years time.
Despite the rapid escalation of
healthcare costs, research into
healthcare economic solutions has not
taken center stage. Nutrition is a
foundation of preventive medicine in
our healthcare system, and it is
postulated that better health outcomes
can be achieved for dollars spent by
ensuring proper nutrition of the
population.
Health economic issues in the U.S.
healthcare delivery system have gained
increased prominence with President
Obama’s expressed desire to ‘‘raise
health care’s quality and lower its
costs.’’ The National Institutes of Health
Clinical and Translational Science
Award Program has also recognized the
importance of ‘‘enhancing the adoption
of best practices in the community,’’
VerDate Nov<24>2008
19:02 Dec 28, 2009
Jkt 220001
including assessment of the costs and
effectiveness of prevention and
treatment strategies. The potential
benefits of health economic analysis
applied to health policy include:
identifying important factors affecting
resource allocation in the setting of
increasingly complex, uncertainty-laden
medical detection and treatment
advances; specifying a basis for
allocating resources among diseases and
in prevention versus detection, versus
treatment; reminding decision-makers
about the reality of limited resources;
and, offering a rational approach to
decision-making when resources are
limited.
In view of the current interest in
health economics and the potential
societal benefit of incorporating health
economics as a part of translational
science, the NIH/ODS will host this dayand-a-half long workshop to bring
together U.S. and international
academicians, researchers, policymakers
and regulators to address the following
key areas and questions specifically as
applied to nutrition interventions:
• State of the Science: What are the
health economic methods currently
used to judge burden of illness,
interventions or healthcare policies, and
what new research methodologies are
available (or are needed, i.e. what are
critical knowledge or methodological
gaps or barriers?)
• Research Applications: What are
the current and planned evidence-based
health economic research activities in
nutrition at the NIH, CDC, AHRQ,
USDA, FDA, CMS, OMAR, etc. and
what are the activities in other
countries?
• Regulatory and Policy Maker
Perspectives: Once these research goals
have been met, how can they assist
regulatory and policy makers with
nutrition policy decision-making?
The workshop will consist of three
half-day sessions which will cover the
key areas identified above. Sessions will
feature focused podium presentations,
with each session concluding with a
panel discussion. The workshop will
conclude with a summary of the
discussions, identification of knowledge
gaps, and suggestions for future research
initiatives.
The current sponsors of this meeting
are the NIH Office of Dietary
Supplements and the National Center
for Complementary and Alternative
Medicine.
Registration
Space is limited and will be filled on
a first-come first-served basis. There is
no registration fee to attend the
workshop. To register please forward
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
68845
your name and complete mailing
address, including phone number, via email to Mr. Mike Bykowski at
mbykowski@csionweb.com. Mr.
Bykowski will be coordinating the
registration for this meeting. If you wish
to make an oral presentation during the
meeting, you must indicate this when
you register and submit the following
information: (1) A brief written
statement of the general nature of the
comments that you wish to present, (2)
the name and address of the person(s)
who will give the presentation, and (3)
the approximate length of time that you
are requesting for your presentation.
Depending on the number of people
who register to make presentations, we
may have to limit the time allotted for
each presentation. If you do not have
access to e-mail please call Mr.
Bykowski at 301–670–0270.
Dated: December 18, 2009.
Paul M. Coates,
Director, Office of Dietary Supplements,
National Institutes of Health.
[FR Doc. E9–30683 Filed 12–28–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–D–0591]
Guidance to Pharmacies on Advance
Compounding of Tamiflu Oral
Suspension to Provide for Multiple
Prescriptions; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
entitled ‘‘Guidance to Pharmacies on
Advance Compounding of Tamiflu Oral
Suspension to Provide for Multiple
Prescriptions.’’ This guidance describes
the circumstances in which FDA will
not object to certain compounding of
Tamiflu Oral Suspension in advance of
receiving prescriptions.
DATES: Submit electronic or written
comments on agency guidances at any
time.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
E:\FR\FM\29DEN1.SGM
29DEN1
]]>Agencies
[Federal Register Volume 74, Number 248 (Tuesday, December 29, 2009)]
[Notices]
[Page 68845]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-30683]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Economic Analysis of Nutrition Interventions: Methods, Research
and Policy
Notice
Notice is hereby given of the National Institutes of Health (NIH)
Office of Dietary Supplements (ODS) Economic Analysis of Nutrition
Interventions Workshop to be held February 23-24, 2010 at the Bethesda
North Marriott Hotel & Conference Center in Bethesda, Maryland, 20852.
Summary
In 2008, healthcare expenditures in the U.S. were estimated to be
17% of GDP, and these projected expenditures were largely associated
with chronic disease. Medicare beneficiaries spent a median of 16% of
their incomes on healthcare, and if current trends persist, a family
earning $60,000 ``gross wage base'' will be spending more than 41% of
wages on healthcare in 10 years time. Despite the rapid escalation of
healthcare costs, research into healthcare economic solutions has not
taken center stage. Nutrition is a foundation of preventive medicine in
our healthcare system, and it is postulated that better health outcomes
can be achieved for dollars spent by ensuring proper nutrition of the
population.
Health economic issues in the U.S. healthcare delivery system have
gained increased prominence with President Obama's expressed desire to
``raise health care's quality and lower its costs.'' The National
Institutes of Health Clinical and Translational Science Award Program
has also recognized the importance of ``enhancing the adoption of best
practices in the community,'' including assessment of the costs and
effectiveness of prevention and treatment strategies. The potential
benefits of health economic analysis applied to health policy include:
identifying important factors affecting resource allocation in the
setting of increasingly complex, uncertainty-laden medical detection
and treatment advances; specifying a basis for allocating resources
among diseases and in prevention versus detection, versus treatment;
reminding decision-makers about the reality of limited resources; and,
offering a rational approach to decision-making when resources are
limited.
In view of the current interest in health economics and the
potential societal benefit of incorporating health economics as a part
of translational science, the NIH/ODS will host this day-and-a-half
long workshop to bring together U.S. and international academicians,
researchers, policymakers and regulators to address the following key
areas and questions specifically as applied to nutrition interventions:
State of the Science: What are the health economic methods
currently used to judge burden of illness, interventions or healthcare
policies, and what new research methodologies are available (or are
needed, i.e. what are critical knowledge or methodological gaps or
barriers?)
Research Applications: What are the current and planned
evidence-based health economic research activities in nutrition at the
NIH, CDC, AHRQ, USDA, FDA, CMS, OMAR, etc. and what are the activities
in other countries?
Regulatory and Policy Maker Perspectives: Once these
research goals have been met, how can they assist regulatory and policy
makers with nutrition policy decision-making?
The workshop will consist of three half-day sessions which will
cover the key areas identified above. Sessions will feature focused
podium presentations, with each session concluding with a panel
discussion. The workshop will conclude with a summary of the
discussions, identification of knowledge gaps, and suggestions for
future research initiatives.
The current sponsors of this meeting are the NIH Office of Dietary
Supplements and the National Center for Complementary and Alternative
Medicine.
Registration
Space is limited and will be filled on a first-come first-served
basis. There is no registration fee to attend the workshop. To register
please forward your name and complete mailing address, including phone
number, via e-mail to Mr. Mike Bykowski at mbykowski@csionweb.com. Mr.
Bykowski will be coordinating the registration for this meeting. If you
wish to make an oral presentation during the meeting, you must indicate
this when you register and submit the following information: (1) A
brief written statement of the general nature of the comments that you
wish to present, (2) the name and address of the person(s) who will
give the presentation, and (3) the approximate length of time that you
are requesting for your presentation. Depending on the number of people
who register to make presentations, we may have to limit the time
allotted for each presentation. If you do not have access to e-mail
please call Mr. Bykowski at 301-670-0270.
Dated: December 18, 2009.
Paul M. Coates,
Director, Office of Dietary Supplements, National Institutes of Health.
[FR Doc. E9-30683 Filed 12-28-09; 8:45 am]
BILLING CODE 4140-01-P
